Previous Close | 1.11 |
Open | 1.11 |
Bid | 1.05 x 200 |
Ask | 1.13 x 1000 |
Day's Range | 1.09 - 1.15 |
52 Week Range | 1.09 - 8.30 |
Volume | 152,066 |
Avg. Volume | 438,908 |
Market Cap | 6.287M |
Beta | 1.06 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.08 |
Earnings Date | May 9, 2018 - May 14, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 26.25 |
Durham’s Heat Biologics (Nasdaq: HTBX) is eyeing a number of important milestones this year and looking to bank about $15.5 million in an offering of common stock and warrants.
- Plans Interim Lung Cancer Phase 2 Readout in Q4 2018 and Final Readout in Q2 2019 - Expects to File IND and Enroll First Patient in ComPACT Trial in Q4 2018 - Anticipates Receipt of $6.9 Million in CPRIT ...
In this analysis, my focus will be on developing a perspective on Heat Biologics Inc’s (NASDAQ:HTBX) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...
100% of non-muscle invasive bladder cancer patients who generated an immune response to low dose HS-410 and also received standard of care BCG remain disease-free after 2 years DURHAM, NC / ACCESSWIRE ...
On the heels of disclosing last week that the company had adopted a stockholder rights plan – otherwise known as a "poison pill" for protection against hostile takeovers – Durham’s Heat Biologics and its subsidiary Pelican Therapeutics have recruited some new scientific expertise.
DURHAM, NC / ACCESSWIRE / March 19, 2018 / Heat Biologics, Inc. (''Heat'') (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, along ...
DURHAM, NC / ACCESSWIRE / March 14, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, ...
DURHAM, NC / ACCESSWIRE / March 13, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, ...
DURHAM, NC / ACCESSWIRE / March 12, 2018 / Heat Biologics, Inc. ("Heat" or the "Company") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's ...
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
DURHAM, NC / ACCESSWIRE / March 2, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, ...
- Tumor Shrinkage and Disease Control Demonstrated in a Majority of Evaluable Patients - HS-110 + Nivolumab Combination Showed Durable Responses in Difficult-to-treat Low TIL Patients and Low PD-L1 Patients, ...
Event to Be Webcast Live DURHAM, NC / ACCESSWIRE / February 26, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
DURHAM, NC / ACCESSWIRE / February 20, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
DURHAM, NC / ACCESSWIRE / February 14, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
DURHAM, NC / ACCESSWIRE / February 7, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
NEW YORK, NY / ACCESSWIRE / February 1, 2018 / U.S. markets rallied late Wednesday to close in the green, with the Dow Jones and S&P 500 posting their best monthly gain since March 2016. The Dow Jones ...
Event will Highlight Clinical Data on First 35 Patients Dosed with HS-110 Plus Checkpoint Inhibitor Nivolumab (Opdivo®) DURHAM, NC / ACCESSWIRE / January 30, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), ...
On the heels of Argos Therapeutics (ARGS) executing a one-for-twenty reverse stock split , another Durham-based biopharmaceutical company Heat Biologics (HTBX) has undertaken a one-for-ten reverse stock split of its own. Last year, Heat outlined a new strategy moving forward, focused on combination therapies for the treatment of cancer .
In this article, I will take a quick look at Heat Biologics Inc’s (NASDAQ:HTBX) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure of aRead More...
DURHAM, NC / ACCESSWIRE / December 7, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
Categories: Yahoo FinanceGet free summary analysis Heat Biologics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Heat Biologics, Inc. – Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Newlink Genetics Corporation, Cascadian Therapeutics Inc., Celldex Therapeutics, Inc., Onconova Therapeutics Inc. and Xencor, Inc. ... Read more (Read more...)